Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BIOMM S.A.
Takeda spins out Oak Hill Bio, Lupin and Axantia will co-develop filgrastim biosimilar and Xbiome licenses skin ulcer candidate from Aurealis.
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
With global rights to TTP's soft-mist inhalation platform, Lupin gets access to the drug delivery system used by Boehringer Ingelheim for Spiriva Respimat and it will be interesting to watch pricing as Lupin leverages the aerosolization technology across respiratory products. Meanwhile, the company has entered a partnership with Biomm for marketing its Neulasta biosimilar in Brazil.
Indian pharma firm Lupin has partnered with Biomm to market its proposed Neulasta biosimilar in Brazil, as it comes to the end of a tumultuous 2021.
- Large Molecule
- Other Names / Subsidiaries
- Savicevic Participacoes SA